Lumbrokinase Research Update 2013 October
By Bryan Rosner on Oct 17, 2013 in Boluoke | comments(0)
Microvascular impairment is a key factor in the development of diabetic peripheral neuropathy (DPN). Currently conventional treatment towards DPN is often less than satisfactory, leaving many DPN patients in agony and poor quality of life.
Lumbrokinase is excellent in restoring circulatory health, including microcirculation. The attached file shows that lumbrokinase was statistically better than B12 injections in improving peripheral neuropathy, muscle tone, and deep tendon reflex (P<0.01).
The study did not specify the product name of the particular lumbrokinase. However, the dosage of 460mg TID matches one of the lumbrokinase brand approved in China, and each 230mg contains 300,000 lumbrokinase units. (Whereas 20mg of Boluoke already contains 300,000 lumbrokinase units)
Now, imagine how much better your results will be if you add Boluoke to your DPN protocol!
http://www.lymebook.com/LumbroTxDiabetesPeripheralNeuropathy2003.pdf
